Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. ( (JP:4882) ) has issued an update.
Perseus Proteomics Inc. announced that its drug candidate, PPMX-T003, intended for treating aggressive NK cell leukemia, has been selected for the Drug Discovery Support Program for Orphan drugs by Japan’s AMED. This selection supports the ongoing clinical trials, which have been extended by a year, and provides a subsidy of 100 million yen to aid in trial expenses, potentially impacting the company’s financial forecast for FY2026/3.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. operates in the biotechnology industry, focusing on the research and development of therapeutic drugs. The company specializes in creating treatments for rare diseases, with a particular emphasis on orphan drugs, which are medications for conditions affecting a small percentage of the population.
YTD Price Performance: 16.37%
Average Trading Volume: 792,805
Technical Sentiment Consensus Rating: Sell
Current Market Cap: Yen9.64B
For an in-depth examination of 4882 stock, go to TipRanks’ Stock Analysis page.